Two acquisitions of cell therapy companies could take them in almost opposite directions.
The collapse of Rubius’s first attempt to demonstrate the worth of its red blood cell platform proves that this company should never have gone public.
Another trial seems to suggest that adding VEGF blockade to Parp inhibition does little for patients without tumour mutations.
The CS1 approach to treating multiple myeloma was once thought capable of matching CD38, but that train left the station some time ago.
Despite Astrazeneca stacking the odds in its favour Imfinzi’s Danube trial, in first-line bladder cancer, reads out negatively.
A private Belgian biotech reckons Tigit is the new PD-1, a view Roche’s progress could validate.
A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.
Karyopharm’s newly approved myeloma drug, Xpovio, has shown promise in earlier lines of therapy, but toxicity could still cap its potential.
The cell therapy player, aiming to take TILs out of academia into a commercial setting, has surged on unsubstantiated takeover rumours.